Abstract
The choline transporter and choline kinase enzyme frequently are overexpressed in malignancy. Therefore, positron-emitter-labeled compounds derived from choline have the potential to serve as oncologic probes for positron emission tomography. The fluorine-18 (18F)-labeled choline derivative fluorocholine (FCH) in particular has demonstrated potential utility for imaging of a variety of neoplasms, including those of the breast, prostate, liver, and brain. The pharmacokinetics of FCH and other choline tracers allow for whole-body imaging within minutes of injection while still achieving high tumor-to-background contrast in most organs, including the brain. These features, along with the possibility of imaging malignancies that have proved elusive with the use of 18F-fluorodeoxyglucose positron emission tomography support further clinical investigations of 18F-labeled choline tracers.
Original language | English (US) |
---|---|
Pages (from-to) | 420-428 |
Number of pages | 9 |
Journal | Seminars in Nuclear Medicine |
Volume | 37 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2007 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging